Biopharma Quarterly Dealmaking Statistics, Q4 2018

A look at financing, M&A and alliance activity October-December 2018

20 Feb 2019

• By Amanda Micklus and Maureen Riordan

At $10.9bn, biopharma financing was at its lowest quarter of the year. GSK’s $5.1bn acquisition of oncology player Tesaro led M&As. And 13 partnerships exceeded the $1bn mark, led by two agreements focused on RNAi.

Biopharma financing in the fourth quarter ended 2018 on a low note, with companies raising an aggregate $10.9bn – a 25% decrease from Q3’s $14.6bn, and the lowest-valued quarter in terms of dollar value in 2018 (see Exhibit 1).

Open Media